Randomized Trial Comparing Biofeedback With and Without Tilt Table Testing in Adults with Vasovagal Syncope

What this Trial Is About

Researchers are evaluating the benefit of adding tilt table testing to biofeedback and standard care in patients with certain or highly likely vasovagal syncope. This condition causes fainting due to a sudden drop in heart rate and blood pressure. The trial aims to compare outcomes between patients receiving biofeedback with tilt table testing and those receiving biofeedback without tilt table testing, as current evidence on the value of tilt table testing is lacking. Participants are randomly assigned to one of two groups one group receives biofeedback and standard care along with tilt table testing, while the other group receives biofeedback and standard care without tilt table testing. Tilt table testing is used as a diagnostic tool to provoke syncope under controlled conditions. The study explores whether this provocation improves patient management and outcomes. During the study, participants will be monitored for syncope recurrence, time until the first syncope event, near-syncope episodes, health technology assessments, and quality of life over a 12-month follow-up period after enrollment. Researchers will collect data on these outcomes to evaluate the impact of tilt table testing on the condition. The study is scheduled to begin in October 2025 and continue until March 2028.

Assesment of the Clinical Benefit of Provocation on Tilt-table in SYNCope Patients, TiltSYNC-trial